NO20013853L - Heteroberlamidines, methylamidines and guanidines as protease inhibitors - Google Patents

Heteroberlamidines, methylamidines and guanidines as protease inhibitors

Info

Publication number
NO20013853L
NO20013853L NO20013853A NO20013853A NO20013853L NO 20013853 L NO20013853 L NO 20013853L NO 20013853 A NO20013853 A NO 20013853A NO 20013853 A NO20013853 A NO 20013853A NO 20013853 L NO20013853 L NO 20013853L
Authority
NO
Norway
Prior art keywords
methylamidines
heteroberlamidines
guanidines
protease inhibitors
protease
Prior art date
Application number
NO20013853A
Other languages
Norwegian (no)
Other versions
NO20013853D0 (en
NO324887B1 (en
Inventor
Carl R Illig
Nalin L Subasinghe
James B Hoffman
Kenneth J Wilson
M Jonathan Rudolph
Juan Jose Marugan
Original Assignee
Dimensional Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dimensional Pharm Inc filed Critical Dimensional Pharm Inc
Publication of NO20013853D0 publication Critical patent/NO20013853D0/en
Publication of NO20013853L publication Critical patent/NO20013853L/en
Publication of NO324887B1 publication Critical patent/NO324887B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NO20013853A 1999-02-09 2001-08-07 Compound, Use and Method of Preparing Such Compound, Pharmaceutical Preparation comprising Such Compound, and In Vitro Method for Inhibition of a Protease NO324887B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24706299A 1999-02-09 1999-02-09
PCT/US1999/018065 WO2000047578A1 (en) 1999-02-09 1999-08-11 Heteroaryl amidines, methylamidines and guanidines as protease inhibitors

Publications (3)

Publication Number Publication Date
NO20013853D0 NO20013853D0 (en) 2001-08-07
NO20013853L true NO20013853L (en) 2001-10-09
NO324887B1 NO324887B1 (en) 2007-12-27

Family

ID=22933398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013853A NO324887B1 (en) 1999-02-09 2001-08-07 Compound, Use and Method of Preparing Such Compound, Pharmaceutical Preparation comprising Such Compound, and In Vitro Method for Inhibition of a Protease

Country Status (19)

Country Link
EP (1) EP1150979A1 (en)
JP (1) JP2002536446A (en)
KR (1) KR20010098982A (en)
CN (1) CN1337961A (en)
AU (1) AU5671799A (en)
BG (1) BG105866A (en)
BR (1) BR9917036A (en)
CA (1) CA2362390A1 (en)
CZ (1) CZ20012858A3 (en)
EA (1) EA200100882A1 (en)
HU (1) HUP0201475A2 (en)
IL (1) IL144560A0 (en)
MX (1) MXPA01008084A (en)
NO (1) NO324887B1 (en)
NZ (1) NZ513701A (en)
PL (1) PL351767A1 (en)
SK (1) SK11422001A3 (en)
WO (1) WO2000047578A1 (en)
ZA (1) ZA200106849B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1152759A2 (en) * 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
UA80131C2 (en) * 2002-05-28 2007-08-27 Dimensional Pharm Inc Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
CN100513398C (en) 2002-12-03 2009-07-15 Axys药物公司 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
US7482376B2 (en) 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
WO2005007601A2 (en) * 2003-07-10 2005-01-27 Achillion Pharmaceuticals, Inc. Substituted arylthiourea derivatives useful as inhibitors of viral replication
AU2005215510A1 (en) 2004-02-12 2005-09-01 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl) complexes, and methods of use thereof
EP2344453B1 (en) 2008-10-09 2016-12-28 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Activators of human pyruvate kinase
CN105017187B (en) 2009-07-08 2017-10-24 德米拉(加拿大)公司 TOFA analogs for treating skin disorder or morbid state
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
AU2012209295B2 (en) * 2011-01-25 2016-06-30 The Regents Of The University Of Michigan Bcl-2/Bcl-xL inhibitors and therapeutic methods using the same
AR086744A1 (en) * 2011-06-28 2014-01-22 Nippon Soda Co HETEROCICLIC COMPOUND CONTAINING NITROGEN AND FUNGICIDE FOR USE IN AGRICULTURE AND GARDENING
EP2606726A1 (en) * 2011-12-21 2013-06-26 Bayer CropScience AG N-Arylamidine-substituted trifluoroethylsulfide derivatives as acaricides and insecticides
US9745328B2 (en) 2013-02-04 2017-08-29 Janssen Pharmaceutica Nv Flap modulators
TWI644899B (en) 2013-02-04 2018-12-21 健生藥品公司 Flap modulators
BR112020019804A2 (en) * 2018-03-30 2021-01-05 Sumitomo Chemical Company, Limited HETEROCYCLIC COMPOUND AND ARTHROPOD FEVER CONTROL COMPOSITION CONTAINING THE SAME
CN109020837A (en) * 2018-07-27 2018-12-18 广东省石油与精细化工研究院 A kind of preparation method of 2- substituted-phenyl-B amidine hydrochloric acid salt

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220654A (en) * 1979-06-04 1980-09-02 Merck & Co., Inc. Cyclic imidazole cyanoguanidines
US4424367A (en) * 1982-08-19 1984-01-03 Norwich Eaton Pharmaceuticals, Inc. 5-(4-Aminophenyl)-2-thiophenecarboximidamide hydrochloride hemihydrate
JPS59139357A (en) * 1983-01-28 1984-08-10 Torii Yakuhin Kk Amidine derivative
DE3427865A1 (en) * 1984-07-27 1986-02-06 Torii & Co., Tokio/Tokyo Amidino compounds, process for their preparation and pharmaceutical compositions containing these compounds
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors
GB9312761D0 (en) * 1993-06-21 1993-08-04 Wellcome Found Amino acid derivatives
US5821267A (en) * 1993-10-21 1998-10-13 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
TW414795B (en) * 1996-07-01 2000-12-11 Yamanouchi Pharma Co Ltd A thiophene derivative and the pharmaceutical composition
DE19632773A1 (en) * 1996-08-14 1998-02-19 Basf Ag New thrombin inhibitors
PE121699A1 (en) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma BICYCLE HETERO CYCLES DISSTITUTED AS INHIBITORS OF THROMBIN
KR100689923B1 (en) * 1998-01-26 2007-03-09 애보트 게엠베하 운트 콤파니 카게 Thrombin Inhibitors
WO1999037611A1 (en) * 1998-01-26 1999-07-29 Basf Aktiengesellschaft Heterocyclic amidines as callicrein protease inhibitors
AU765072B2 (en) * 1998-02-09 2003-09-11 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines as protease inhibitors, in particular as urokinase inhibitors
BR9815786A (en) * 1998-03-31 2000-11-21 Warner Lambert Co Quinolones as serine protease inhibitors
BR9815785A (en) * 1998-03-31 2000-12-05 Warner Lambert Co Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
PL343317A1 (en) * 1998-03-31 2001-08-13 Warner Lambert Co Benzoxazinones/benzothiazinones as serine protease inhibitors

Also Published As

Publication number Publication date
NZ513701A (en) 2001-09-28
CN1337961A (en) 2002-02-27
SK11422001A3 (en) 2002-04-04
PL351767A1 (en) 2003-06-16
EA200100882A1 (en) 2002-04-25
NO20013853D0 (en) 2001-08-07
AU5671799A (en) 2000-08-29
CA2362390A1 (en) 2000-08-17
BG105866A (en) 2002-06-28
NO324887B1 (en) 2007-12-27
CZ20012858A3 (en) 2002-05-15
BR9917036A (en) 2002-07-30
IL144560A0 (en) 2002-05-23
MXPA01008084A (en) 2004-09-10
HUP0201475A2 (en) 2003-10-28
EP1150979A1 (en) 2001-11-07
KR20010098982A (en) 2001-11-08
WO2000047578A1 (en) 2000-08-17
JP2002536446A (en) 2002-10-29
ZA200106849B (en) 2002-11-20

Similar Documents

Publication Publication Date Title
DK1268431T3 (en) 3-Cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
CY2012007I2 (en) PEPTIDEMIMETIC PROTEASE INHIBITORS
ATE524441T1 (en) VLA-4 INHIBITORS
NO20034042L (en) Metalloproteinases inhibitors
NO20053356D0 (en) Aminindazole derivatives and their use as kinase inhibitors.
ATE237329T1 (en) METALLOPROTEASE INHIBITORS
NO20014483D0 (en) Amine derivatives as protease inhibitors
NO20015065L (en) Pyrazolobenzodiazepines as CDK2 inhibitors
ATE304015T1 (en) TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRION METALLOPROTEINASE INHIBITORS
ATE325091T1 (en) ASPARTYL PROTEASE INHIBITORS
DK1511734T3 (en) Compounds, Preparations and Methods
NO20034032D0 (en) Metalloproteinases inhibitors
NO20042719L (en) Substituted 2-amino-cycloalkanecarboxamides and their use as protease inhibitors
NO20013853D0 (en) Heteroberlamidines, methylamidines and guanidines as protease inhibitors
NO20013675D0 (en) 2,3,4,5-Tetrahydro-1H- [1,4) benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
NO20035328D0 (en) New compounds and preparations as catheps inhibitors
FI20002044A0 (en) Naphthalene derivatives which inhibit Comt enzymes
MA25758A1 (en) PROTEASE INHIBITORS.
DK1214302T3 (en) Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones and their use as lipase inhibitors
NO20025005L (en) protease inhibitors
DK1453852T3 (en) Selective arylguanidine peptides as urokinase inhibitors
NO20032328L (en) protease inhibitors
DK1367055T3 (en) Isoquinolinylcarboxamides and their use as anticonvulsants
NO20011654D0 (en) Benzamide derivatives as thrombin inhibitors
DK1487802T3 (en) 2,3-diaryl-pyrazolidine derivatives as neurotensin-degrading enzyme inhibitors

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees